Maci 3CM x 5CM implant sheets
Ended Awarded
- Contract number
- SPE2DB25FUJSL
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $61,539
Award facts
- Contract value 100% obligated
- $61,538.77 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $61,538.77 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for MACI 3cm x 5cm implant sheets. The award, issued on September 18, 2025, with an ultimate completion date of October 9, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $499.999 billion acquisition strategy supporting Department of Defense pharmaceutical and medical supply requirements worldwide.
MACI (matrix-applied characterized autologous mesenchymal cell implant) sheets represent specialized surgical products used in orthopedic and regenerative medicine applications. DMS Pharmaceutical Group's established performance across diverse product categories—including oncology treatments, biologics, vaccines, and specialty surgical products—demonstrates its capability as a critical supplier within the federal military medical supply chain. The company's registration in the System for Award Management since July 2001 and consistent delivery order activity reflect its stable operational presence in government pharmaceutical contracting, positioning it to reliably fulfill the Defense Logistics Agency's recurring medical supply needs across military healthcare facilities.
Quick answers
Who was awarded contract SPE2DB25FUJSL?
SPE2DB25FUJSL was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 18, 2025.
How much is contract SPE2DB25FUJSL worth?
The government has obligated $61,539 on SPE2DB25FUJSL.
Is contract SPE2DB25FUJSL an order under another contract?
Yes. SPE2DB25FUJSL is a delivery order under SPE2DB25D9365, an indefinite delivery contract.
Was contract SPE2DB25FUJSL competed?
The extent of competition for SPE2DB25FUJSL was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award